The National Football League (NFL) and its teams won’t face renewed antitrust claims over the relocation of the Raiders to Las Vegas after the Northern District of California court found the city of Oakland didn’t show an antitrust injury.
“Whatever harm may result from allowing teams to relocate to the city with the highest bid is not harm redressable under the antitrust laws,” the US District Court for the Northern District of California stated Thursday, April 30, reported Bloomberg Law.
Oakland filed suit in December, alleging the NFL and Raiders violated antitrust laws by approving the move to Las Vegas, and claimed doing so amounted to a group boycott of Oakland. Outside attorneys have taken the city’s case on a contingency basis, meaning it comes at no cost to the city. The city also alleged in its suit that the Raiders violated the League’s relocation policy by not seriously negotiating with Oakland and Hall of Famer Ronnie Lott’s group, which proposed to help finance a new stadium at the Coliseum.
But attorneys for the Raiders and NFL wrote that the competition between Las Vegas and Oakland was not a violation of antitrust laws, which are designed to promote competition and prohibit monopolies. The city did not suffer antitrust injury, the attorneys said, but rather “the injury flows from an increase in competition” and “another community’s willingness to make an offer better than Oakland’s.”
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan